Impact of PCSK9 monoclonal antibodies on circulating hs-CRP levels: a systematic review and meta-analysis of randomised controlled trials.

ABSTRACT:

Objective

To evaluate the potential effects of proprotein convertase subtilisin/kexin type 9 monoclonal antibody (PCSK9-mAb) on high-sensitivity C reactive protein (hs-CRP) concentrations.

Design

A systematic review and meta-analysis of randomised controlled trials.

Data sources

PubMed, MEDLINE, the Cochrane Library databases, ClinicalTrials.gov and recent conferences were searched from inception to May 2018.

Eligibility criteria for selecting studies

All randomised controlled trials that reported changes of hs-CRP were included.

Results

Ten studies involving 4198 participants were identified. PCSK9-mAbs showed a slight efficacy in reducing hs-CRP (-0.04 mg/L, 95% CI: -0.17 to 0.01) which was not statistically different. The results did not altered when

SUBMITTER: Cao YX 

PROVIDER: S-EPMC6173233 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature